MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2025.08.030

Медицинская библиотека · Urologic oncology · 2025

PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance.

Gusev Andrew, Rumpf Florian, Zlatev Dimitar, Twum-Ampofo Jeffrey K, Gore John L, Dahl Douglas M, Wszolek Matthew F, Efstathiou Jason, Lee Richard J, Blute Michael L, Salari Keyan, Feldman Adam S

СтатьяПеревод в очереди

Аннотация

PURPOSE: The safety and efficacy of active surveillance (AS) for men with prostate cancer (PCa) depend on accurate risk stratification at diagnosis and during follow-up. Initial PSA density (PSAD) has been associated with the risk of AS progression when measured at diagnosis, yet few studies have examined the impact of changes in PSAD during follow-up. We investigated whether serial PSAD measurements during AS were prognostic of subsequent biopsy grade progression.

PATIENTS AND

METHODS

We queried our institutional AS database to identify men with Grade Group 1 PCa, ≥ 2 prostate biopsies, and ≥ 2 PSAD measurements at least 1 year apart. The median follow-up time was 5.9 years. The primary outcome was grade progression on subsequent AS biopsy. The utility of trending PSAD during AS was evaluated using 2 models: PSAD change over time (PSAD velocity) in a cross-validated logistic regression and serial PSAD measurements in a Cox proportional hazards model with time-varying covariates.

RESULTS

A total of 453 patients were included, of whom 137 met the primary outcome of biopsy pathological grade progression. Among the rich multivariate model, serial PSAD measurements had the highest concordance index (0.75) as a prognostic marker of biopsy progression. Patients with a net positive PSAD velocity (increasing PSAD over AS) had an OR of 1.97 (95% CI 1.26-3.11) and those with a PSAD value ≥0.15 ng/ml2 at any point during AS had a HR of 3.70 (95% CI 2.45-5.60).

CONCLUSIONS

Our data suggest that serial PSAD measurements and PSAD velocity are strong independent prognostic markers of biopsy grade progression in AS. As prostate volume and PSA measurements are already part of AS protocols, monitoring PSAD trends over time confers no additional cost and should be integrated into clinical practice to improve risk stratification.

Для цитирования: Gusev Andrew, Rumpf Florian, Zlatev Dimitar, Twum-Ampofo Jeffrey K, Gore John L, Dahl Douglas M, Wszolek Matthew F, Efstathiou Jason, Lee Richard J, Blute Michael L, Salari Keyan, Feldman Adam S. PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance.. Urologic oncology. 2025. DOI: 10.1016/j.urolonc.2025.08.030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.